In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Lilly comes out on top with $70/share ImClone bid

Executive Summary

Trumping a $62 per share bid first launched by Bristol-Myers Squibb in July, Eli Lilly has now agreed to acquire targeted cancer care company ImClone Systems for $70 per share (a 53% premium to ImClone's market average ten days prior to the initial Bristol announcement). The deal value for all of ImClone's 87mm outstanding shares and additional vested stock options is estimated at about $6.5bn. As of September 30, 2008, ImClone reported about $890mm in cash and cash equivalents.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies